Can the optimal treatment duration be determined in bismuth-containing therapies for Helicobacter pylori eradication?
| Errataetall: |
CommentOn: Chin Med J (Engl). 2022 Dec 20;135(24):2899-2910. - PMID 36579940 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Clinical and experimental medicine - 23(2023), 7 vom: 13. Nov., Seite 4037-4039 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ding, Yu-Ming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 02.11.2023 Date Revised 08.11.2023 published: Print-Electronic CommentOn: Chin Med J (Engl). 2022 Dec 20;135(24):2899-2910. - PMID 36579940 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10238-023-01099-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358123356 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358123356 | ||
| 003 | DE-627 | ||
| 005 | 20231226074056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10238-023-01099-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM358123356 | ||
| 035 | |a (NLM)37310656 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ding, Yu-Ming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Can the optimal treatment duration be determined in bismuth-containing therapies for Helicobacter pylori eradication? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2023 | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Chin Med J (Engl). 2022 Dec 20;135(24):2899-2910. - PMID 36579940 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Bismuth |2 NLM | |
| 650 | 7 | |a U015TT5I8H |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Clarithromycin |2 NLM | |
| 650 | 7 | |a H1250JIK0A |2 NLM | |
| 700 | 1 | |a Li, Yue-Yue |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental medicine |d 2001 |g 23(2023), 7 vom: 13. Nov., Seite 4037-4039 |w (DE-627)NLM113691408 |x 1591-9528 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:7 |g day:13 |g month:11 |g pages:4037-4039 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10238-023-01099-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 7 |b 13 |c 11 |h 4037-4039 | ||